BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; low-dose infigratinib, a treatment option for children living with hypochondroplasia, a skeletal dysplasia closely related to achondroplasia which is in Phase 2/3. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. The company has license and collaboration agreements with the Alexion Pharma International Operations Unlimited Company, Leland Stanford Junior University and Leidos Biomedical Research, Inc., and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.

BridgeBio Pharma Inc.

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sarepta Therapeutics (SRPT – Research Report), Dan...

Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (SRPT), Danaher (DHR) and BridgeBio Pharma (BBIO)

Evercore ISI analyst Cory Kasimov maintained a Buy rating on BridgeBio Pharma today and set a price target of $100.00. According to TipRanks, Kasim...

Evercore ISI Sticks to Its Buy Rating for BridgeBio Pharma (BBIO)

Raymond James analyst Martin Auster reiterated a Buy rating on BridgeBio Pharma today and set a price target of $85.00. According to TipRanks, Aust...

BridgeBio Pharma (BBIO) Gets a Buy from Raymond James

In a report released today, Andrew Tsai from Jefferies maintained a Buy rating on BridgeBio Pharma, with a price target of $85.00. Tsai covers the ...

Jefferies Reaffirms Their Buy Rating on BridgeBio Pharma (BBIO)

Wells Fargo analyst Tiago Fauth maintained a Buy rating on BridgeBio Pharma yesterday and set a price target of $84.00. The company’s shares closed...

Wells Fargo Keeps Their Buy Rating on BridgeBio Pharma (BBIO)

Bank of America Securities analyst Jason Zemansky maintained a Buy rating on BridgeBio Pharma today and set a price target of $85.00. Zemansky cove...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BBIO	$78.24	+1.26%	1.29M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BBIO	$78.24	+1.3%	1.29M
3
4
5
6

BBIO

BBIO

No Data Available

Get BridgeBio Pharma Inc. Data in Excel

Get BridgeBio Pharma Inc. Data in Excel